fbpx
Brokers NewsCryptocurrencyEconomic CalendarEducationMarket newsTrading IdeasTrading Tips

Investors Will be Closely Watching Johnson & Johnson This Week and Here’s Why

Earnings will become major interest for investors this week as some of the largest U.S. companies from a wide range of sectors are set to report Q2 2021 earnings. 

GET TRADING SIGNALS »

As the U.S. economic recovery keeps going very well after better than expected rollouts of COVID vaccines, investors are expected to concentrate on inflationary pressures and find out whether they are squeezing corporate margins. Taking advantage of earnings optimism, all three biggest U.S. indices continued their upward movement this year, with the S&P 500 and the NASDAQ 100 Index trending at their peak levels.

Below, we’ve presented a stock investors are closely watching as Q1 earnings season ramps into full swing:

 Johnson & Johnson

Global healthcare behemoth Johnson & Johnson (NYSE:JNJ) is going to report its Q2 earnings before the market opens on Wednesday, July 21st. Following the experts’ consensus forecast, the company is going to report $2.29 EPS on sales of $22.5 billion for the period.

In addition to the quarterly data, investors will find out more useful information about the rollout of its COVID-19 vaccine and its effectiveness in defending against the fast spreading Delta variant.

J&J’s vaccine has fought hard to get broad traction as production problems occured and after a short break in use as regulators researched reports that some people who had received J&J’s vaccine suffered dangerous blood clots shortly after the shot. The break was lifted after 10 days on April 23rd.

Despite a short pause in vaccination, J&J’s underlying business remains very strong as the U.S. economy keeps rebounding and hospitals slowly increase elective surgeries after the COVID-19 imposed disruption, which hurt the company’s device business in 2020. Shares of J&J are trading 7% up this year. The company finished Friday’s trades at $168.10.

 

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button
Close
Close